NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196)

Matrix of consultees and commentators

Manufacturers/sponsorsNovartis Pharmaceuticals (imatinib)Patient/carer groupsAfiya TrustBeating Bowel CancerBlack Health AgencyBladder and Bowel FoundationBowel Cancer InformationBowel Cancer UKCancer 52Cancer Black CareCancer Black CareCancer EqualityColostomy AssociationEqualities National CouncilGIST Support UKHelen Rollason Cancer Patients VoiceMarie Curie Cancer SupportMaggie's CentresMarie Curie Cancer CareMuslim Council of BritainMuslim Health NetworkOchreOesophageal Patients Association	Consultees	Commentators (no right to submit or appeal)
	Manufacturers/sponsors Novartis Pharmaceuticals (imatinib) Patient/carer groups Afiya Trust Beating Bowel Cancer Black Health Agency Bladder and Bowel Foundation Bowel Cancer Information Bowel Cancer UK Cancer 52 Cancer Black Care Cancer Equality Colostomy Association Equalities National Council GIST Support UK Helen Rollason Cancer Charity IA Independent Cancer Support Maggie's Centres Marie Curie Cancer Care Muslim Council of Britain Muslim Health Network Ochre Oesophageal Patients Association Ostomy Lifestyle Rarer Cancers Foundation Sarcoma UK South Asian Health Foundation Specialised Healthcare Alliance	appeal)GeneralAllied Health Professionals FederationBoard of Community Health Councils in WalesBritish National FormularyCare Quality CommissionCommissioning Support Appraisals ServiceDepartment of Health, Social Services and Public Safety for Northern IrelandHealthcare Improvement ScotlandMedicines and Healthcare Products Regulatory AgencyNational Association of Primary CareNational Pharmacy AssociationNHS AllianceNHS ConfederationScottish Medicines ConsortiumComparator manufacturer(s)NoneRelevant research groupsBowel and Cancer ResearchCochrane Upper Gastrointestinal and Pancreatic Diseases GroupCORE- Digestive Disorders FoundationHealth Research AuthorityInstitute of Cancer ResearchMRC Clinical Trials UnitNational Cancer Research Institute

National Institute for Health and Care Excellence

Matrix for the technology appraisal of imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196)

Consultees	Commentators (no right to submit or appeal)
 Professional groups Association of Cancer Physicians Association of Clinical Pathologists Association of Surgeons of Great Britain and Ireland Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland British Association of Surgical Oncology British Geriatrics Society British Institute for Radiology British Psychosocial Oncology Society (BPOS) British Sarcoma Group British Society of Gastroenterology Cancer Network Pharmacists Forum Cancer Research UK Royal College of Anaesthetists Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal College of Surgeons Royal College of Surgeons Royal College of Radiologists Royal College of Surgeons Royal Society of Medicine Society and College of Radiographers United Kingdom Clinical Pharmacy Association UK Health Forum United Kingdom Oncology Nursing Society 	 Research Institute for the Care of Older People Evidence Review Group Southampton Health Technology Assessment Centre (SHTAC) National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups Public Health England Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.